



# Roadshow Presentation

**MARCH 2024** 

Clayton Astles
Chief Executive Officer

**Brendan Maher**Chief Finance Officer

Revenue from customers up 11% to \$22.8 million

Teknocorp acquisition completed and term sheet for Amentco announced

Software and SMA revenues up 11% million to \$4.0 million

Accumulated orders yet to be delivered grows to an all-time high of \$44.4 million

NPAT down slightly due to investment in strategic growth initiatives

Increased investment in research and development to \$2.3 million.





# RECENT CONTRACT WINS



## CANADA St. Pauls Hospital

The St. Pauls Hospital contract represents the largest single contract award in Austco Healthcare's history, and includes over 1100 full IP patient stations, 1200 clinical workflow terminals, and Webservices interfaces for EMR and RTLS systems integrations.

\$2.6 MILLION

### SINGAPORE Mt. Elizabeth Hospital

The Mount Elizabeth contract provides a significant strategic opportunity for Austco Healthcare. The contract includes Austco's innovative Tacera system, featuring RTLS-ready call points, Pulse Mobile, and industry-leading clinical workflow solution

\$3.8 MILLION

### SINGAPORE Jurong Health

This \$3.8 million contract includes a refresh of the Tacera Nurse Call platform at the state-of-the-art 700-bed Ng Teng Fong General Hospital (NTFGH) and the 400-bed Jurong Community Hospital (JCH), both part of the Jurong Health Campus.



#### AUSTRALIA Whittlesea Hospital

Teknocorp, which was recently acquired by Austco Healthcare, was awarded this \$1.2 million contract to deliver state-of-the-art access control and CCTV solutions for the upcoming Whittlesea Community Hospital.



#### USA Encompass Health

Over the past two months, our US subsidiary has been awarded three new hospital contracts from Encompass Health totaling \$2.5 million. The contracts are for the supply and installation of our industry leading IP Nurse call solution and Tacera Pulse software platform.






# App Station Apps

Annunciator

Communications (VoIP audio)

Virtual call points (Workflow) released with 4.27

Hallway sign / Room screen released with 4.28



# 1-Button Badge & Charger

Paired with staff or residents

IP rated for water immersion

Worn around wrist or as pendant

Replace badge without removing bracelet

Gyroscope for fall detection

Minimum 7 days battery life





# Wander Prevention

Procurement strategy privileges vendors who tick more boxes
Initial rollout is white/black list of locations
Location events can activate relays for door locks

#### **ASSET TRACKING**

Most likely integrated 3rd party hardware

To be useful, requires mapping





## Pulse Display Driver

Pulse Device – no more Touchduty

Administered through Pulse Manage

Customised for each facility

Roadmap: additional apps

#### In production now (4.28)





# Master Callpoint

Single room controller


Microphone array for voice-assist applications

Built-in RTLS available

At home in Aged or Acute care

Magnetic connectors

Austco's new design language





# Fall detection, behaviour analysis

No cameras, no wearables, no buttons

#### **Fall Detection**

- multiple "levels" of fall, all independently actionable and reportable

#### **Automation**

- Each device monitors multiple "zones"
- Based on zone and other factors, can automate aspects of the system: lights, alerts, door locks, messaging

#### **Comprehensive Reporting**

- all events logged for reporting.
- Data accumulated over time allows for predictive
   analysis intervention before an emergency occurs





# Redesigned Mobile Application

Modern framework for easy updates

Communications features: voice and secure text

Pending tasks and reminders for room

Room "inbox" for messages

Control anything tied to an integrated system: lights, thermostat, blinds, etc.





# Strategic Goals





## FY24 Strategic Plan: Revenue Strategies

	OBJECTIVE	STRATEGY
01	Drive Organic Growth	<ul> <li>Build the sale pipeline leveraging the new sales resources added over the prior year.</li> <li>Continue to look to add additional resellers in all markets</li> <li>Target national accounts in all regions</li> </ul>
02	<b>Growth by Acquisition</b>	<ul> <li>Target feature rich and software capable resellers</li> <li>Target US, Australia and Europe competitors to accelerate market access</li> <li>Emerging technology that compliments our core products (IP)</li> </ul>
03	Increase Software & SMA Revenues	<ul> <li>Educate the market on what is possible with Austco's software solutions (early-engagement)</li> <li>Focus our salespeople &amp; resellers on software selling</li> </ul>



## FY24 Strategic Plan: Revenue Strategies

OBJECTIVE		STRATEGY
04	Increase Brand Awareness	<ul> <li>Implement global marketing strategies that boost our brand.</li> <li>Early engagement with industry influencers.</li> <li>Lead generation programs across all regions</li> </ul>
05	Expand across Europe and Middle East	<ul> <li>Target feature rich and software capable resellers</li> <li>Target competitors' resellers to accelerate market access</li> <li>Target resellers with industry experience</li> </ul>



## FY24 Strategic Plan: Operational Strategies

OBJECTIVE		STRATEGY
01	Improve Systems	<ul> <li>Zoho CRM Improvements</li> <li>Order fulfillment portal (delivery status)</li> </ul>
02	Continue to Innovate	<ul> <li>Release new products and product enhancements on a regular basis</li> <li>Continue to gather internal and external input</li> </ul>
03	<b>Product Training</b>	<ul> <li>Make training material accessible through a training portal</li> <li>Recruit a dedicated global technical and end-user trainer</li> <li>Improve processes to ensure training is provided ahead of new product releases</li> </ul>





# M&A AMENTCO ACQUISITION



## About Amentco

Amentco is a Systems Integrator specialising in the Installation, Service and Maintenance of Nurse Call, Customised Workflow, Real-Time Locating (RTLS) Security, CCTV and Access Control Systems. Amentco designs and installs integrated solutions that help enhance patient care, improve efficiency and minimise risk. Its loyal customer base consists of enterprises in public and private sectors, predominantly operating in healthcare, and aged-care, sectors across Queensland, Australia.

#### **ENTITY**

Amentco Enterprise Group Pty Ltd

#### **STATUS**

Binding term sheet signed 25 February 2024

#### TRANSACTION VALUE

\$10.6 million



### Strategic Rationale

The acquisition of Amentco aligns with Austco's strategic objectives of expanding its direct sales capability, driving accelerated growth, and enhancing its portfolio of solutions to better serve the Australian healthcare market. Unlike other regions within the Austco Group, which already employ a direct sales model alongside resellers, Australia's market structure relies on state-based resellers. By integrating Amentco into its operations, Austco aims to enhance its direct sales approach, extend its market reach, and establish a more unified presence across the country.

#### **Benefits for Austco Healthcare**

- Expansion of Market Presence
- Diversification of Products and Services
- Revenue Synergies
- Operational Efficiencies
- Talent Acquisition
- Enhanced Competitive Advantage




### Financial Terms

Amentco will be acquired on a cash-free, debt-free basis for a total purchase price of \$10,600,00 based on 3.5 times financial year 2023 EBITDA and will be subject to customary completion adjustments for working capital, any net debt assumed and an earnout.

#### The Purchase Price is based on:

- a) an upfront cash payment (subject to adjustments) of \$5,000,000;
- b) the issue at completion of \$2,000,000 of Austco shares; and
- c) an earnout amount calculated on the annualised FY24 EBITDA and FY25 EBITDA of Amentco multiplied by 3.5 times less the upfront payment.



# Integration Plan

Austco intends to merge Amentco's extensive business with its current operations, spanning hundreds of sites. Key personnel from Amentco will be retained to facilitate a seamless transition for both customers and employees. This strategic alignment is expected to unlock significant revenue synergies by leveraging the complementary strengths of both entities. By facilitating cross-selling opportunities for products and services and optimizing operational processes, Austco anticipates a strengthened market position and enhanced value proposition for its customers.





### OUTLOOK

With a clear strategic vision and a commitment to innovation, Austco Healthcare is positioned for meaningful growth for the foreseeable future.

#### ORDER BOOK CONTINUES TO GROW

Since reporting our results, there has been a further increase in our Open Sales Orders, now at \$44.4 million.

#### INNOVATION AND PRODUCT DEVELOPMENT

We will continue to prioritise innovation and product development, investing in the development of solutions that address the evolving needs of healthcare organisations worldwide.

#### **SOFTWARE & SMA REVENUE**

Increased interest in high-margin workflow and software solutions.

#### MERGERS AND ACQUISITIONS (M&A)

By strategically integrating complementary businesses, technologies, and talent, we will strengthen our competitive edge and drive sustainable growth






# > Financial Performance

# REVENUE FROM CUSTOMERS

Revenue from customers was up 11% to \$22.8 million compared to pcp. Revenue from customers was also up on our 2HFY23 revenues of \$21.4 million, despite 2H being traditionally stronger than 1H.

Notably, this growth is attributed to a strategic product mix adjustment, with a decrease in installation revenues and an increase in equipment revenues, reflecting our ongoing commitment to optimising our offerings to meet market demands.

This sustained growth not only reaffirms our position as a leader in the industry but also underscores our commitment to delivering value to our stakeholders and driving long-term success for Austco Healthcare.





# SOFTWARE AND SMAREVENUES

Growth in Software and Service Maintenance Agreement (SMA) revenues by 11% to \$4.0 million, accounting for 17% of total revenues, underscores our commitment to developing cuttingedge software solutions.

As we continue to invest in the development of innovative software solutions, Software and SMA revenues will continue to play a vital role in driving our company's growth and success.

Moving forward, we are confident that our continued focus on software innovation will further solidify our position as a leader in the healthcare technology sector. With Software and SMA revenues at the forefront of our revenue streams, we are positioned to capitalise on emerging opportunities and drive sustained success for Austro Healthcare.






# OPEN SALES ORDERS

Open Sales Orders (OSO) represent confirmed contracted orders from customers that have not yet been fulfilled and, as such, no revenue recognised.

Despite recording growth in recognised revenues, we continue to win new work at a greater rate and as such, our OSO continues to build.

A substantial increase in our Open Sales Orders to \$44.4 million, inclusive of a \$3.3 million contribution from our recently acquired Teknocorp, serves as a strong foundation for our ongoing revenue growth trajectory.

This figure is a significant increase from our Open Sales Order book one year ago of \$20.3 million reported in February 2023.



# GROSS PROFIT AND MARGIN




Gross margins at 51.9% were down on pcp of 54.8% and the 52.2% delivered in 2HFY23. The reduction was driven by:

- Consumption of higher cost raw materials procured during COVID to maintain product delivery certainty, the balance of which is expected to be consumed in 2HFY24;
- Higher revenue contribution from two lower margin markets (Latin America and Asia); and
- Contribution from lower margin Teknocorp projects. The strategic initiatives of this acquisition will assist in increasing the margin and revenue contribution of this business.



27


# REPORTED EARNIGS




The Company's continued investment in R&D, recruitment and M&A transaction costs over these reporting periods have consumed the financial benefits of revenue growth.

Outside of M&A costs we do not expect significant additional costs growth such that future revenue and margin growth would contribute to increased profits going forward.

#### **REPORTED NPAT**





## CASH & DEBT




Cash on hand was \$5.0 million at 31 December 2023, up \$0.3 million from June 2023.

Borrowings of \$1.5 million have been used to fund the acquisition of Teknocorp.

Cash generated from operating activities of \$1.9 million assisted in limiting the amount of borrowing required.



### DISCLAIMER



This publication does not constitute an offer, invitation or recommendation for the sale or purchase of any securities in any jurisdiction.

References to, and the explanation of, legislation and regulatory issues in this Publication are indicative only and should not be relied on. They do not purport to summarise all relevant legislation and regulatory issues or to be a full explanation of any particular matter.

#### **Past Performance**

Past performance information given in this Publication is given for illustrative purposes and should not be relied upon as an indication of future performance.

#### **Forward Looking Statements**

The information contained herein involves elements of subjective judgment and analysis and may be identified by words such as 'may', 'could', 'believes', 'expects', 'intends' or other words that involve risk and uncertainty (collectively, forward looking statements). Any forward looking statements expressed in this Publication are subject to change without notice. They do not constitute, and should not be regarded as, a representation that the relevant results will actually be achieved or that the underlying assumptions upon which forward looking statements may be based are valid or reasonable. Actual results may vary from the forward looking statements and such variations may be material.

#### **Other Information**

All financial amounts contained in this Publication are expressed in Australian currency unless otherwise stated. Any discrepancies between totals and sums and components in tables contained in this Publication are due to rounding.

#### **Disclaimer**

Other than to the extent required by law, neither Austco nor any of their

respective affiliates, associates, shareholders, directors, officers, employees, agents, representatives and advisers (the Austco Parties) make any representation or warranty (express or implied) as to, and assume responsibility or liability for, the authenticity, origin, validity, accuracy or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this Publication or in any accompanying, previous or subsequent material or presentation in connection with the subject matter of this Publication.

Without limiting the foregoing, none of the Austco Parties:

- makes or purports to make any statement or representation (including, but not limited to, any representation with respect to any forward looking statement) contained in this Publication;
- is responsible for the contents of this Publication;
- has verified the accuracy or completeness of this Publication; or
- is liable in any way for any misstatement in, or errors in or omission from, this Publication or in any accompanying, previous or subsequent material or presentation in connection with the subject matter of this Publication, except and then only to the extent required by law.

#### **United States**

In particular, this Publication is not an offer of securities for sale in the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the United States Securities Act of 1933 (the Securities Act)). Austco, its affiliates and related bodies corporate are not and will be registering any securities under the Securities Act or the securities laws of any state of the United States or any other jurisdiction other than the Commonwealth of Australia.

This document has been prepared for publication in Australia and may not be released or distributed in the United States or to U.S. persons. Failure to comply with this directive may result in a violation of the Securities Act and/or another applicable law of the United States or another jurisdiction.





#### **CLAYTON ASTLES**

CEO & Executive Director Aust: +61 411 531 170 US: +1 682 803 1222



#### **BRENDAN MAHER**

CFO & Company Secretary Aust: +61 439 369 551

